Abstract
Cholecystokinin octapeptide (CCK-8) is prevalent as a co-transmitter in the mesolimbic dopamine pathway. The effect of proglumide, a CCK-8 antagonist, on two acute and one chronic behavioral models of dopamine function was tested. First, haloperidol was used to inhibit stereotypies induced by apomorphine in rats. Pre-administration of proglumide significantly shifted the haloperidol dose response curve to the left. Second, rats were injected in the left caudate nucleus with kainic acid. Three weeks later, haloperidol was used to inhibit apomorphine-induced circling. Pre-administration of proglumide had no effect on this haloperidol dose response curve. Third, either proglumide, haloperidol, or combined treatment was administered to rats for 2 weeks. In proglumide-treated animals, a significant increase in 3H-spiperone binding sites in the nucleus accumbens was observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bean AJ, Baldy WJ, Martin GE (1985) Chronic proglumide increases [3H] spiperone binding in the rat brain. Eur J Pharmacol 117:97–101
Bunney BS, Grace AA, Hommer DW, Skirboll LR (1982) Effect of cholecystokinin on the activity of midbrain dopaminergic neurons. In: Costa F, Trabucchi M (eds) Regulatory peptides: From molecular biology to function. Raven, New York, pp 429–436
Bunney BS, Chiodo LA, Freeman AS (1985) Further studies on the specificity of proglumide as a selective cholecystokinin antagonist in the central nervous system. Ann NY Acad Sci 448:345–351
Chang RSL, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, Goetz MA, Albers-Schonberg G, Patchett AA, Liesch JM, Hensens OD, Springer JP (1985) A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from aspergillus alliaceus. Sciece 230:177–179
Chiodo LA, Bunney BS (1983) Proglumide: selective antagonism of excitatory effects of cholecystokinin in central nervous system. Science 219:1449–1451
Cohen SL, Knight M, Tamminga CA, Chase TN (1982) Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy. Eur J Pharmacol 83:213–222
Costall B, Naylor RJ (1973) The role of telencephalic dopaminergic systems in the mediation of apomorphine-stereotyped behaviour. Eur J Pharmacol 24:8–24
Crawley JN, Stivers JA, Blumstein LK, Paul SM (1983) Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence. J Neurosci 5:1972–1985
Crawley JN, Stivers JA, Hommer DW, Skirboll LR, Paul SM (1986) Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide. J Pharmacol Exp Ther 236:320–330
Dumbrille-Ross A, Seeman P (1984) Dopamine receptor elevation by cholecystokinin. Peptides 5:1207–1212
Hahne WF, Jensen RT, Lemp GF, Gardner JD (1981) Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists. Proc Natl Acad Sci USA 78:6304–6308
Hokfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, Markey K (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 285:476–478
Katsuura G, Itoh S, Rehfeld JF (1984) Effects of cholecystokinin on apomorphine-induced changes of motility in rats. Neuropharmacology 23:731–734
Klawans HL, Goetz GG, Perlik S (1980) Tardive dyskinesia review and update. Am J Psychiatry 137:900–908
Konig J, Klippel R (1963) The rat brain: A stereotactic atlas. In: Krieger RE (ed) New York
Kovacs GL, Szabo G, Penke B, Telegdy G (1981) Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice. Eur J Pharmacol 69:313–319
Lowry OH, Rosenbrough NJ, Farr AL, Randell RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275
Makovec F, Chiste R, Bani M, Pacini MA, Setnikar I, Rovati LA (1985) New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity. Arzneim-Forsch/Drug Res 35:1048–1051
Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: A review. Schizophr Bull 2:19–76
Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 43:669–676
Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM (1984) Neuroleptic-induced decreases in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225:954–957
Rehfeld JF (1985) Neuronal cholecystokinin: One or multiple transmitters? J Neurochem 44:1–10
Schneider LH, Alpert JE, Iversen SD (1983) CCK-8 modulation of mesolimbic dopamine: Antagonism of amphetamine-stimulated behaviors. Peptides 4:749–753
Schneider LH, Gibbs J, Smith GP (1986) Proglumide fails to increase food intake after an ingested preload. Peptides 7:135–140
Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32:229–313
Skirboll LR, Grace AA, Hommer DW, Rehfeld J, Goldstein M, Hokfelt T, Bunney BS (1981) Peptide-monoamine coexistence: Studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience 6:2111–2124
Voigt MM, Wang RY (1984) In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin. Brain Res 296:189–193
Wennogle LP, Steel DJ, Petrack B (1985) Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe. Life Sci 36:1485–1492
Zetler G (1981a) Central depressant effects of caerulein and cholecystokinin octapeptide (CCK-8) differ from those of diazepam and haloperidol. Neuropharmacology 20:277–283
Zetler G (1981b) Differential cataleptogenic and antistereotypic effects of caerulein and haloperidol. Neuropharmacology 20:681–686
Zetler G (1985) Antistereotypic effects of cholecystokinin octapeptide (CCK-8), ceruletide and related peptides on apomorphine-induced gnawing in sensitized mice. Neuropharmacology 24:251–259
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Csernansky, J.G., Glick, S. & Mellentin, J. Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function. Psychopharmacology 91, 440–444 (1987). https://doi.org/10.1007/BF00216008
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00216008